TY - JOUR
T1 - A baseline metabolomic signature is associated with immunological CD4 + T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients
AU - Rodríguez-Gallego, Esther
AU - Gómez, Josep
AU - Pacheco, Yolanda M.
AU - Peraire, Joaquim
AU - Viladés, Consuelo
AU - Beltrán-Debón, Raúl
AU - Mallol, Roger
AU - López-Dupla, Miguel
AU - Veloso, Sergi
AU - Alba, Verónica
AU - Blanco, Julià
AU - Cañellas, Nicolau
AU - Rull, Anna
AU - Leal, Manuel
AU - Correig, Xavier
AU - Domingo, Pere
AU - Vidal, Francesc
N1 - Funding Information:
The current work was supported by grants from the Fondo de Investigacion Sanitaria (PI10/02635, PI13/ 00796, PI13/01912, PI14/01693, PI14/0700, PI14/ 0063 and PI16/00503) Instituto de Salud Carlos III; Fondos Europeos para el Desarrollo Regional (FEDER); Programa de Suport als Grups de Recerca AGAUR (2014SGR250 and 2009SGR1061); the Gilead Fellowship Program (GLD13/00168 and GLD14/293); the Junta de Andalucía, Consejería de Economía, Innova-ción, Ciencia y Empleo (Proyecto de Investigación de Excelencia; CTS2593); the Red de Investigación en Sida (RIS) (RD12/0017/0002, RD12/0017/0005, RD12/ 0017/0014, RD12/0017/0029 and RD16/0025/0006) Instituto de Salud Carlos III, Spain. F.V. and P.D. are supported by a grant from the Programa de Intensifica-ción de Investigadores, Instituto de Salud Carlos III (INT11/240, INT12/282 and INT12/383, INT13/232, INT15/226 and INT15/140). Y.M.P. was supported by the Fondo de Investigación Sanitaria through the ‘Miguel Servet’ program (CPII13/00037) and by the Consejería de Salud y Bienestar Social of Junta de Andalucía through the ‘Nicolás Monardes’ program (C-0010/13). A.R. is supported by a grant from the Acció Instrumental d’Incorporació de Científics i Tecnòlegs (PERIS SLT002/16/00101), Departament de Salut, Generalitat de Catalunya. We want to particularly acknowledge the patients enrolled in this study for their participation and the BioBanc IISPV (B.0000853 + B.0000854) integrated in the Spanish National Biobanks Platform (PT13/0010/ 0029 & PT13/0010/0062) for its collaboration.
Publisher Copyright:
© Copyright 2018 The Author(s). Published by Wolters Kluwer Health, Inc.
PY - 2018/3/13
Y1 - 2018/3/13
N2 - Objectives: Poor immunological recovery in treated HIV-infected patients is associated with greater morbidity and mortality. To date, predictive biomarkers of this incomplete immune reconstitution have not been established. We aimed to identify a baseline metabolomic signature associated with a poor immunological recovery after antiretroviral therapy (ART) to envisage the underlying mechanistic pathways that influence the treatment response. Design: This was a multicentre, prospective cohort study in ART-naive and a pre-ART low nadir (<200 cells/μl) HIV-infected patients (n = 64). Methods: We obtained clinical data and metabolomic profiles for each individual, in which low molecular weight metabolites, lipids and lipoproteins (including particle concentrations and sizes) were measured by NMR spectroscopy. Immunological recovery was defined as reaching CD4 + T-cell count at least 250 cells/μl after 36 months of virologically successful ART. We used univariate comparisons, Random Forest test and receiver-operating characteristic curves to identify and evaluate the predictive factors of immunological recovery after treatment. Results: HIV-infected patients with a baseline metabolic pattern characterized by high levels of large high density lipoprotein (HDL) particles, HDL cholesterol and larger sizes of low density lipoprotein particles had a better immunological recovery after treatment. Conversely, patients with high ratios of non-HDL lipoprotein particles did not experience this full recovery. Medium very-low-density lipoprotein particles and glucose increased the classification power of the multivariate model despite not showing any significant differences between the two groups. Conclusion: In HIV-infected patients, a baseline healthier metabolomic profile is related to a better response to ART where the lipoprotein profile, mainly large HDL particles, may play a key role.
AB - Objectives: Poor immunological recovery in treated HIV-infected patients is associated with greater morbidity and mortality. To date, predictive biomarkers of this incomplete immune reconstitution have not been established. We aimed to identify a baseline metabolomic signature associated with a poor immunological recovery after antiretroviral therapy (ART) to envisage the underlying mechanistic pathways that influence the treatment response. Design: This was a multicentre, prospective cohort study in ART-naive and a pre-ART low nadir (<200 cells/μl) HIV-infected patients (n = 64). Methods: We obtained clinical data and metabolomic profiles for each individual, in which low molecular weight metabolites, lipids and lipoproteins (including particle concentrations and sizes) were measured by NMR spectroscopy. Immunological recovery was defined as reaching CD4 + T-cell count at least 250 cells/μl after 36 months of virologically successful ART. We used univariate comparisons, Random Forest test and receiver-operating characteristic curves to identify and evaluate the predictive factors of immunological recovery after treatment. Results: HIV-infected patients with a baseline metabolic pattern characterized by high levels of large high density lipoprotein (HDL) particles, HDL cholesterol and larger sizes of low density lipoprotein particles had a better immunological recovery after treatment. Conversely, patients with high ratios of non-HDL lipoprotein particles did not experience this full recovery. Medium very-low-density lipoprotein particles and glucose increased the classification power of the multivariate model despite not showing any significant differences between the two groups. Conclusion: In HIV-infected patients, a baseline healthier metabolomic profile is related to a better response to ART where the lipoprotein profile, mainly large HDL particles, may play a key role.
KW - HIV-1
KW - antiretroviral therapy
KW - biomarkers
KW - metabolomics
KW - poor immune recovery
UR - http://www.scopus.com/inward/record.url?scp=85044183307&partnerID=8YFLogxK
U2 - 10.1097/QAD.0000000000001730
DO - 10.1097/QAD.0000000000001730
M3 - Article
C2 - 29280761
AN - SCOPUS:85044183307
SN - 0269-9370
VL - 32
SP - 565
EP - 573
JO - AIDS
JF - AIDS
IS - 5
ER -